New insider activity at United Therapeutics ( (UTHR) ) has taken place on December 16, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Director Christopher Patusky recently sold 1,000 shares of United Therapeutics stock, amounting to a transaction worth $495,950.
Recent Updates on UTHR stock
Recent developments in United Therapeutics have led to multiple analysts raising their price targets for the company’s stock. UBS increased its target due to positive advancements in clinical studies, particularly the first clinical xenotransplantation in the EXPAND study, which showcases the company’s innovative approach in the biotech field. RBC Capital and H.C. Wainwright also raised their targets, reflecting confidence in the company’s growth prospects and successful execution of its strategic initiatives. Morgan Stanley’s adjustment highlights the market’s optimistic outlook on the company’s future performance.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
United Therapeutics’ strong financial performance and positive earnings call are the most significant factors contributing to the score. The company’s robust revenue growth, profitability, and strategic initiatives provide a solid foundation for future growth. Technical analysis supports a bullish trend, although valuation metrics suggest the stock is fairly valued. The absence of a dividend yield indicates a focus on reinvestment for growth. Potential risks include market competition and regulatory uncertainties.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
YTD Price Performance: 38.89%
Average Trading Volume: 614,480
Technical Sentiment Signal: Buy
Current Market Cap: $21.27B